Research
Hormonal
Adolescent depression is a strong longitudinal predictor of binge eating symptoms and eating disorder diagnosis in young adulthood for both men and women.
If you or your adolescent child is experiencing depression, be aware that this is a strong predictor for developing binge eating and eating disorders later in life. This applies to both men and women. Addressing depression early may help prevent these eating-related health problems.
GoodSupportsHIGH confidence
Depression at W1 was strongly associated with binge symptoms at W3 among both men and women (OR = 3.51, CI = 1.91–6.39; p < 0.001; OR = 2.43, CI = 1.78–3.31, p < 0.001, respectively), and with ED diagnosis among both men and women (OR = 5.72, CI = 1.92–17.0; p < 0.001; OR = 2.01, CI = 1.48–2.76, p < 0.001, respectively).
Why this rating
Large longitudinal sample, prospective design, highly significant p-values.
Source
Longitudinal predictors of dieting and disordered eating among young adults in the U.S.
Janet M. Liechty et al. · International Journal of Eating Disorders · 2013
DOI 10.1002/eat.22174
cohort · n=14322Cited 192×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Adolescent dieting and extreme weight loss behaviors (EWLB) prospectively predict the onset of EWLB in young adulthood, particularly among women.Good
- Adolescent body image distortion (BID) prospectively predicts the onset of dieting in young adulthood for both men and women.Good
- A cumulative risk index of adolescent psychosocial and behavioral factors (depression, BID, dieting, EWLB) predicts higher odds of eating pathology in young adulthood, with gender-specific patterns.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →